NWPF

News ArchivesRead News

Parkinson's Biomarker Could Be Only Skin Deep

Thursday November 14, 2013

Eleanor McDermid

medwireNews - Deposits of α-synuclein in cutaneous nerves could represent a noninvasive biomarker for Parkinson’s disease (PD), say researchers.

Abnormal α-synuclein deposits have been reported in other parts of the peripheral nervous system, such as the olfactory nerves, vagus nerve, and colonic submucosal plexus, but unlike these, the skin is simple and noninvasive to biopsy.

Using fluorescent microscopy, Roy Freeman (Harvard Medical School, Boston, Massachusetts, USA) and team detected α-synuclein in skin biopsies of all 20 PD patients (average disease duration of 4.2 years) and 14 age- and gender-matched controls who participated in the study.

Previous studies using a similar approach did not detect α-synuclein in all participants. Freeman et al attribute this largely to previous researchers’ use of antibodies to phosphorylated α-synuclein, whereas they used a more general α-synuclein antibody.

As reported in Neurology, the team detected α-synuclein in autonomic fibers in the dermal layer, but not in nociceptive sensory fibers. Although all participants had some α-synuclein present, PD patients had a significantly higher ratio of α-synuclein to nerve fiber density than controls, at about 0.8 versus 0.2 for the pilomotor (adrenergic) fibers and about 0.3 versus less than 0.05 for the sudomotor (sympathetic cholinergic) fibers.

This pattern was consistent for the three sites biopsied: the distal leg; distal thigh; and proximal thigh.

PD patients had reduced pilomotor fiber density relative to controls, and this correlated with higher α-synuclein ratios. Sudomotor nerve density was similar in patients and controls, yet higher α-synuclein ratios still correlated with lower nerve density in the patients.

Increased α-synuclein ratios in PD patients also correlated with autonomic dysfunction and higher Hoehn and Yahr scores.

In an accompanying editorial, William Cheshire (Mayo Clinic, Jacksonville, Florida, USA) and Ronald Pfeiffer (University of Tennessee Health Science Center, Memphis, USA) say: “These findings hold promise that further clues to a deeper understanding of the molecular and neuronal pathology of PD may be accessible just beneath the body's surface where affected autonomic nerves innervate cutaneous structures.”

However, they caution that “[c]linical use of skin biopsies to diagnose or stage PD would be premature at this time.”

McDermid, E. (14 Nov. 2013). medwireNews. Parkinson's Biomarker Could Be Only Skin Deep. www.medwirenews.com.

Recent News

Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 18 - Fighting Parkinson's disease through dance
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show